No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
WGS240517C17500
- 5.30
- 0.000.00%
15min DelayClose May 14 11:03 ET
0.00High0.00Low
0.00Open5.30Pre Close0 Volume0 Open Interest17.50Strike Price0.00Turnover1873.21%IV10.68%PremiumMay 17, 2024Expiry Date3.10Intrinsic Value100Multiplier-7DDays to Expiry2.20Time Value100Contract SizeAmericanOptions Type0.9581Delta0.0268Gamma3.89Leverage Ratio-6.1678Theta0.0000Rho3.72Eff Leverage0.0002Vega
Intraday
- 5D
- 1D
News
GeneDx to Participate in Upcoming Investor Conferences
STAMFORD, Conn., May 22, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will partici
Over $1M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying
Although U.S. stocks closed higher on Wednesday, there were a few notable insider trades.When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the s
GeneDx Holdings(WGS.US) 10% Shareholder Buys US$1.17 Million in Common Stock
$GeneDx Holdings(WGS.US)$ 10% Shareholder Casdin Capital, LLC purchased 50,000 shares of common stock on May 13, 2024 at an average price of $23.3059 for a total value of $1.17 million. This transacti
Express News | GeneDx Shares Are Trading Higher After the Company on Tuesday Reported Better-than-expected Q1 Financial Results
Analysts Are Upgrading GeneDx Holdings Corp. (NASDAQ:WGS) After Its Latest Results
GeneDx Holdings Corp. (NASDAQ:WGS) just released its quarterly report and things are looking bullish. The results were impressive, with revenues of US$62m exceeding analyst forecasts by 26%, and
GeneDx Holdings First Quarter 2024 Earnings: Beats Expectations
Comments
Hello Mooers! ![]()
A quick recap for the month ending April 30, 2024.
![]()
Ten stocks with >300% YTD
![]()
$Swvl Holdings(SWVL.US$718.40%
![]()
$Root Inc(ROOT.US$564.60%
![]()
$Elevation Oncology(ELEV.US$561.08%
![]()
$JanOne(JAN.US$554.05%
![]()
$GeneDx Holdings(WGS.US$520.71%
![]()
$Corbus Pharmaceuticals(CRBP.US$513.25%
![]()
$AGBA Group(AGBA.US$482.90%
![]()
$Janux Therapeutics(JANX.US$431.22%
![]()
$Dave Inc(DAVE.US$4...
A quick recap for the month ending April 30, 2024.
4
1
$GeneDx Holdings(WGS.US$
NEWS
GeneDx Announces Partnership with Komodo Health to Expand Access to World’s Largest Rare Disease Dataset
NEWS
GeneDx Announces Partnership with Komodo Health to Expand Access to World’s Largest Rare Disease Dataset
1
The low P/S of GeneDx Holdings indicates investors expect limited future growth. A recent share price boost hasn't shifted investor perceptions. The low P/S is largely because shareholders are pessimistic about revenue prospects.
Read more
Mars MoooOP :